Development of Prototypes Sample Clauses

The 'Development of Prototypes' clause outlines the obligations and procedures for creating preliminary models or versions of a product or system during a project. It typically specifies the standards, timelines, and approval processes for prototype development, and may detail who is responsible for providing materials, feedback, or testing. By clearly defining these aspects, the clause ensures that both parties understand the expectations and deliverables for prototypes, reducing misunderstandings and facilitating smoother project progression.
Development of Prototypes of Licensed Products Upon selection of an Authorized Source for the first selected Licensed Product within Licensee's Field of License, which Licensee stands ready to procure, develop and market in commercial quantities, Licensee shall promptly and forthwith proceed to procure such selected Licensed Product in prototype form from such an Authorized Source, and upon procurement thereof provide Licensor with a sample thereof.
View SourceView Similar (7)
Development of Prototypes. Upon execution of this Agreement and the Ancillary Agreements by the Parties, NTI shall make a capital contribution to the Company in the amount of Fifty Thousand Dollars ($50,000) U.S., plus such additional amounts that will be sufficient (in NTI’s judgment) to enable the Company to: (a) Pay the reasonable travel expenses of ▇▇▇▇▇▇ to the United States to assist in the design and manufacturing of one or more Prototypes; and (b) Pay the cost of developing and manufacturing one or more Prototypes. NTI’s aggregate financial obligation under this Section 7.5 shall not exceed Fifty Thousand Dollars U.S. ($50,000), unless otherwise agreed by NTI.
View Source
Development of Prototypes. In the second phase Novars will develop prototypes for different applications for specific potential user on a case-by-case basis. BACH & ASSOCIATES, N.Y., N.Y. NON-DISCLOSURE AGREEMENT NON-DISCLOSURE AGREEMENT, made this _____ day of June, 1999, by and between (i) Novars Gesellschaft fur neue Technologien mbH (▇▇▇▇▇▇▇▇▇▇ ▇▇, 82343 Pocking, Germany), its affiliates, parent companies, subsidiaries, officers, directors, employees, contractors, consultants, and their successors and assigns (collectively, "Novars"); Samsung Electronics Co., Ltd. (416 Maetan-dong, Paldal-Du, Suwon, Kyungki-Do, Korea), its affiliates, parent companies, subsidiaries, officers, directors, employees, contractors, consultants, and their successors and assigns (collectively, "Samsung"); and (iii) Manhattan Scientifics, Inc. and Energy Related Devices, Inc. (127 ▇▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇) (collectively, "Company").
View Source

Related to Development of Prototypes

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Protocols Each party hereby agrees that the inclusion of additional protocols may be required to make this Agreement specific. All such protocols shall be negotiated, determined and agreed upon by both parties hereto.

  • Development Reports Beginning six months after Effective Date and ending on the date of first commercial sale of a Licensed Product in the United States, LICENSEE shall report to Cornell progress covering LICENSEE's (and Affiliate's and Sublicensee's) activities and efforts in the development of rights granted to LICENSEE under this Agreement for the preceding six months. The report shall include, but not be limited to, activities and efforts to develop and test all Licensed Products and obtain governmental approvals necessary for marketing the same. Such semi-annual reports shall be due within sixty days (60) of the reporting period and shall use the form as provided herein as Appendix C.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).